Article
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.
Clinical pharmacology and therapeutics - 1 Sept 2012
de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers D R
Abstract excerpt
Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow therapeutic index and highly variable pharmacokinetics. This cross-sectional study in 59 renal transplant patients investigated the relationship among in vivo CYP3A4 activity (assessed using midazolam as a drug probe), CYP3A5 genotype on the one hand, and tacrolimus pharmacokinetics on the other hand, taking into account other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.